In human cells, three closely related RAS genes, termed HRAS, KRAS, and NRAS, encode four highly homologous proteins. RAS proteins are small GTPases involved in a broad spectrum of key molecular and cellular activities, including proliferation and survival among others. Gain-of-function missense mutations, mostly located at codons 12, 13, and 61, constitutively activate RAS proteins and can be detected in various types of human cancers. KRAS is the most frequently mutated, followed by NRAS and HRAS. However, each isoform exhibits distinctive mutation frequency at each codon, supporting the hypothesis that different RAS mutants may lead to distinct biologic manifestations. This review is focused on the differences in signaling and phenotype,...
<p>The RAS family is a group of small GTPases that can become constitutively activated by point muta...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
The RAS oncogenes KRAS, NRAS and HRAS are mutated in one third of human cancers where they exhibit d...
RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-regulated binary on-off switches, w...
ABSTRACTActivating mutations of Ras genes are often observed in cancer. The protein products of the ...
Ras proteins play a crucial role as a central component of the cellular networks controlling a varie...
Oncogenic mutations in the small Ras GTPases KRas, HRas, or NRas render the encoded proteins constit...
Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regardi...
In humans, members of the RAS gene family are mutated in many cancers. There are three homologous RA...
Mutation in one of three RAS genes (i.e., HRAS, KRAS, and NRAS) leading to constitutive activation o...
The genetic alterations in cancer cells are tightly linked to signaling pathway dysregulation. Ras i...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
SummaryOncogenic mutations in the small Ras GTPases KRas, HRas, and NRas render the proteins constit...
Nearly 30% of human cancers have mutations in one of the three RAS genes. Despite over 30 years of d...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
<p>The RAS family is a group of small GTPases that can become constitutively activated by point muta...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
The RAS oncogenes KRAS, NRAS and HRAS are mutated in one third of human cancers where they exhibit d...
RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP–GTP-regulated binary on-off switches, w...
ABSTRACTActivating mutations of Ras genes are often observed in cancer. The protein products of the ...
Ras proteins play a crucial role as a central component of the cellular networks controlling a varie...
Oncogenic mutations in the small Ras GTPases KRas, HRas, or NRas render the encoded proteins constit...
Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regardi...
In humans, members of the RAS gene family are mutated in many cancers. There are three homologous RA...
Mutation in one of three RAS genes (i.e., HRAS, KRAS, and NRAS) leading to constitutive activation o...
The genetic alterations in cancer cells are tightly linked to signaling pathway dysregulation. Ras i...
Oncogenic activation of RAS isoforms leads tumor initiation and progression in many types of cancers...
SummaryOncogenic mutations in the small Ras GTPases KRas, HRas, and NRas render the proteins constit...
Nearly 30% of human cancers have mutations in one of the three RAS genes. Despite over 30 years of d...
SummaryOncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understand...
<p>The RAS family is a group of small GTPases that can become constitutively activated by point muta...
Rat sarcoma virus (RAS) represents the most frequently mutated oncogene family across all malignanci...
The RAS oncogenes KRAS, NRAS and HRAS are mutated in one third of human cancers where they exhibit d...